Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.

This review discusses the clinical features, diagnosis, and treatment options for alopecia areata of the beard and reports no new clinical results.

In this study, permanent alopecia after haematopoietic stem cell transplantation was found in 16% of patients and was significantly associated with conditioning regimens involving busulphan.

This review discusses the potential use of platelet-rich plasma for treating alopecia areata but reports no new experimental findings, noting the need for standardized protocols and larger studies to evaluate its efficacy.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

This study suggests that combining microneedling with ALA-photodynamic therapy may be a promising treatment option for moderate to severe alopecia areata, achieving significant hair regrowth in some patients.

This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.

In this retrospective study, low-dose methotrexate was observed to be effective and well-tolerated in treating recalcitrant alopecia areata multiplex, achieving complete or near-complete hair regrowth in about 90% of patients despite some experiencing elevated liver enzymes and gastrointestinal discomfort.

The cause of alopecia areata was unknown, and while various treatments existed, no best treatment was agreed upon.

In this study, 308-nm excimer light therapy showed significant effects in some patients with treatment-resistant alopecia universalis, suggesting it as a potential alternative therapy.

This study found that topical clobetasol propionate cream provided a modest improvement in hair regrowth for alopecia areata patients, though those with atopy had higher relapse rates after treatment completion.

This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.

This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.

This study found that phototoxic psoralen and ultraviolet A therapy with topical 8-MOP was effective in treating alopecia areata resistant to other treatments, improving hair regrowth with minimal side effects.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

In this study, cyclosporine A stimulated hair growth in mouse vibrissae organ culture by promoting matrix cell proliferation and altering growth factor expression.

This case report describes occipital hair transplantation for therapy-resistant alopecia areata in eyebrows, observing 80% hair re-growth two years post-surgery and suggesting surgical options may be useful for stable cases.

This review discusses various therapeutic options for alopecia areata and reports no new clinical results; treatments may manage symptoms but do not cure the condition.

This article discusses a case of patchy alopecia areata that spares greying hairs but reports no new findings; it refers to existing literature for context.

In this study, corticosteroid injections were found to be more effective than saline for inducing hair regrowth in cases of alopecia areata with long-duration and extensive hair loss.

This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.

This study found that patients with alopecia areata and androgenetic alopecia showed increased c-kit expression and decreased Ki-67 expression in hair follicle cells compared to controls, suggesting a possible feedback mechanism involving stem cell factor signaling.

In this observational study, researchers found that socioeconomic factors and stress significantly influence alopecia areata in patients in the Indian subcontinent.

This article discusses inflammatory perifollicular fibrosis and alopecia but provides no new research findings.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

This article reviews characteristics and mental health impacts of alopecia areata but provides no new clinical findings; future research is encouraged.

This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.

This study found that trichoscopy is essential for evaluating the severity of alopecia areata and predicting treatment responses, contributing to more personalized patient management.

This study reported that intralesional triamcinolone acetonide was more effective than intralesional PRP for treating scalp alopecia areata, with minimal recurrence and side effects like atrophy and hypopigmentation.

In this study, a Chinese Han family with hereditary vitamin D-resistant rickets was found to have a homozygous missense mutation in the VDR gene, and the affected individual uniquely responded well to treatment with oral calcium and low-dose calcitriol.